Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 15 November 2024, 16:33 HKT/SGT
Share:
    

Source: Eisai
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)

TOKYO, Nov 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Japan Ltd announced today that a TV commercial will be broadcast nationwide in Japan from November 15 with the aim of increasing public understanding of MCI (Mild Cognitive Impairment).

MCI refers to the stage between "normal brain function" and "dementia," where the individual can still lead an independent daily life but cognitive functions of the brain, such as memory and judgment, have somewhat declined. If cognitive function further declines from the MCI stage to a state where it disrupts daily life and care becomes necessary, it is then diagnosed as dementia.

In 2022, there were 5.58 million people living with MCI in Japan, accounting for 15.5% of those aged 65 and over, and estimated to reach 6.12 million by 2040. 1 While MCI is often referred to as a precursor to dementia, it doesn’t necessarily progress to dementia. Depending on the cause, the condition may be maintained, or even improved. If you are concerned about forgetfulness, early consultation with a specialist is important for the early detection of MCI and clarification of its cause, through which appropriate measures can be taken to prevent the progression from MCI to dementia.  

This TV commercial tells the story of a mother whose daughter worries for her, always telling her "You just said that earlier". The mother realizes that the forgetfulness she attributed to old age might in fact be due to MCI, leading her to seek medical advice.

A survey2 conducted by Eisai showed that awareness of the term "MCI" was 12%, while understanding of it was only 2%, which is still low. Through this TV commercial, Eisai and Biogen Japan hope to increase awareness of MCI among a broader range of people, thereby raising public interest in cognitive impairment and contributing to the early detection and treatment of MCI.

(1) Research on the Prevalence and Future Projections of Dementia and Mild Cognitive Impairment, 2023 Elderly Health  Promotion Project Grant, Professor Toshiharu Ninomiya, Kyushu University
(2) Internet survey
Target: Japan nationwide, men and women aged 60-70, 2000 responses
Survey period: February 2024
Survey conducted by: Macromill Carenet, Inc.   

About the TV Commercial

Title: MCI Disease Awareness TV Commercial "Don't Miss it, MCI" Edition (15 seconds/30 seconds)
TV Broadcast Start: November 15, 2024
Broadcasting Area: Japan nationwide
Main CM Video: Published on YouTube from November 15
(https://youtube.com/@patients_eisai?si=vLaA-y07QAlORHLa)

About Eisai

Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology, Oncology and Global Health.

Theoria technologies Co., Ltd., a member of the Eisai Group, operates the dementia portal site "Theotol" (https://theotol.soudan-e65.com/), which provides easy-to-understand contents and services for the general public about MCI and various types of dementia, their causes, treatments, as well as caregiving methods and personal experiences. (Japanese only)

About Biogen Japan

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information on Biogen Japan that may be important to investors on our website at https://www.biogen.com/ and social media XLinkedIn, FacebookYouTube

MEDIA CONTACTS
Eisai Co., Ltd.
Public Relations Department
TEL:+81 (0)3-3817-5120

Biogen Japan, Ltd.
Corporate Affairs
TEL:+81-70-1501-4315
E-mail: Japan-PA@biogen.com




Topic: Press release summary
Source: Eisai

Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 11, 2024 13:45 HKT/SGT
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
Dec 5, 2024 10:22 HKT/SGT
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Nov 28, 2024 15:26 HKT/SGT
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
Nov 26, 2024 14:50 HKT/SGT
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: